Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.63 | N/A | -9.61% |
management commentary, guidance changes, and full analysis available with Pro.
| -9.61% |
Tone: Defensive
Management expressed concerns about current market conditions impacting results. They are focused on addressing operational challenges.
Management acknowledged the challenges faced during the quarter.
They highlighted ongoing efforts to stabilize operations and improve performance.
The earnings report indicates that Organon & Co faced difficulties in the fourth quarter, leading to an EPS miss. The stock fell by 8.19% following the announcement, reflecting investor concerns about the company's performance and lack of guidance. Management's defensive tone suggests ongoing challenges that may affect future results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UDR INC REIT
Feb 9, 2026